Gossamer Bio, Inc. (NASDAQ:GOSS) Receives Consensus Recommendation of "Hold" from Brokerages

Key Points

• Consensus "Hold": Ten analysts cover Gossamer Bio with a split view (2 sell, 4 hold, 4 buy) and an average 12-month target price of $5.43.
• Shares very low vs. targets: GOSS opened at $0.35 with a market cap of $81.3M, a 12-month range of $0.32–$3.87 and 50-/200-day moving averages of $1.43 and $2.36, indicating a sustained downtrend.
• Mixed fundamentals: Q1 EPS of ($0.21) missed by $0.01 while revenue beat at $13.8M, but the company reported a deeply negative net margin (-351.49%) and ROE (-1,774.72%), and analysts expect -$0.28 EPS for the fiscal year.

Shares of Gossamer Bio, Inc. (NASDAQ:GOSS - Get Free Report) have been given a consensus recommendation of "Hold" by the ten ratings firms that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $5.4286.

GOSS has been the subject of several recent analyst reports. HC Wainwright decreased their price objective on shares of Gossamer Bio from $10.00 to $5.00 and set a "buy" rating for the company in a report on Friday, March 6th. Royal Bank Of Canada upgraded shares of Gossamer Bio to an "outperform" rating in a report on Tuesday, February 24th. Barclays lowered shares of Gossamer Bio from an "overweight" rating to an "underweight" rating in a research report on Tuesday, February 24th. Cantor Fitzgerald restated a "neutral" rating on shares of Gossamer Bio in a report on Monday, March 23rd. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Gossamer Bio in a research report on Thursday, January 22nd.

Institutional Trading of Gossamer Bio

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. MB Generational Wealth LLC bought a new stake in shares of Gossamer Bio in the third quarter valued at approximately $3,721,000. Corient Private Wealth LLC grew its stake in shares of Gossamer Bio by 8.9% in the second quarter. Corient Private Wealth LLC now owns 3,693,683 shares of the company's stock worth $4,543,000 after acquiring an additional 302,200 shares during the last quarter. Police & Firemen s Retirement System of New Jersey bought a new position in Gossamer Bio during the second quarter worth $53,000. AXQ Capital LP acquired a new position in Gossamer Bio during the 3rd quarter valued at $122,000. Finally, Jones Financial Companies Lllp raised its stake in Gossamer Bio by 136.7% during the 3rd quarter. Jones Financial Companies Lllp now owns 17,360 shares of the company's stock valued at $47,000 after purchasing an additional 10,027 shares during the last quarter. Institutional investors and hedge funds own 81.23% of the company's stock.

Gossamer Bio Stock Performance

GOSS opened at $0.35 on Friday. The firm has a market cap of $81.32 million, a P/E ratio of -0.46 and a beta of 2.08. The business has a 50 day moving average price of $1.43 and a 200 day moving average price of $2.36. Gossamer Bio has a twelve month low of $0.32 and a twelve month high of $3.87.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last announced its quarterly earnings results on Tuesday, March 17th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.01). Gossamer Bio had a negative net margin of 351.49% and a negative return on equity of 1,774.72%. The company had revenue of $13.80 million for the quarter, compared to analyst estimates of $7.53 million. As a group, analysts anticipate that Gossamer Bio will post -0.28 earnings per share for the current fiscal year.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company's lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.